Bone disease in multiple myeloma;Doença óssea em mieloma múltiplo

Revista Brasileira de Hematologia e Hemoterapia

Volumn 29, Issue 1, 2007, Pages 60-66

  Hungria, Vania Tietsche De Moraes ^a,b  

^a FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Biphosphonates; Bone disease; Multiple myeloma; Osteoclast activity

Indexed keywords

EID: 37349011920     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-84842007000100013     Document Type: Review

References (60)

1. Mundy GR, Bertoline DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986;13:291-299.
2. Kyle RA. Multiple myeloma, review of 869 cases. Mayo Clin Proc 1975;50:29-40.
3. Mundy GR, Mechanisms of osteolytic bone destruction. Bone 1991;12(Suppl 1):S1-6.
4. Bataille R, Chappard D, Basle M. Excessive bone resorption in human plasmacytomas: direct induction by tumor cells in vivo. Br J Haematol 1995;90:721-724.
5. Kawano M, Yamamoto I, Iwato K, et al. Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 1989;73:1.646-1.649.
6. Ishimi Y, Mijaura C, Jin CH et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990;145:3.297-3.303.
7. Bataille R, Barlogie B, Lu ZY et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995;86:685-91.
8. Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol 1999;141:195-210.
9. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and ativation. Cell 1998;93:165-176.
10. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
11. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001;98:11.581-11.586.
12. Roux S, Meignin V, Quillard J, et al. RANK (receptor activator of nuclear factor-kappa B) and RANKL expression in multiple myeloma. Br J Haematol 2002;117;86-92.
13. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barillé S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3.527-3.533.
14. Seidel C, Hjertner O, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multile myeloma with lytic bone disease. Blood 2001;98:2.269-2.271.
15. Croucher PI, Shipman CM, Lippitt J, et al. Osteprotegerin inhibits the development of osteolytic bone disease in patients with multiple myeloma. Blood 2001;98:3.534-3.540.
16. Yacobby S, Pearse RN, Johnson CL, Barlogie B, et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-290.
17. Han JH, Choi SJ, Kurihara N, et al. Macropahge inflammatory protein-1 alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappa B ligand. Blood 2001;97:3.349-3.353.
18. Abe M, Hiura K, Wilde J, et al. Role macrophage inflammatory protein (MIP)-1 alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002;100:2.195-2.202.
19. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1[alpha] on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood. In press.
20. Su S, Mukaida N, Wang J, et al. Inhibition of immature erythroid progenitor cell proliferation by macrophage inflammatory protein-1 alpha by interacting mainly mainly with a C-C chemokine receptor, CCR1. Blood 1997;90:605-611.
21. Tsujimoto T, Lisukov IA, Huang N, et al. Plasma cell induce apoptosis of pre-B cells by interacting with bone marrow stromal cells. Blood 1996;87:3.375-3.383.
22. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991;88: 62-66.
23. Tian E, Zhan F, Walker R, et al. The role of the WNT-signaling antagonists DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2.483-2.494.
24. Wahner H, Kyle RA, Beabout JW. Scintigraphic evaluation of te skeleton in multiple myeloma. Mayo Clin Proc 1980; 55:739-746.
25. Woolfenden JM, Pitt MJ, Durie BGM, et al. Comparison of bone scintigraphy and radiography in multiple myeloma. Radiology 1980;134:723-728.
26. Waxman AD, Siemsen JK, Levine AM, et al. Radiographic and radionuclide imaging in multiple myeloma: the role of gallium scintigraphy. J Nucl Med 1981;22:232-236.
27. Abildgaard N, Brixen K, Kristensen JE, et al. Assessment of bone involvement in patients with multiple myeloma using bone densitometry. Eur J Haematol 1996;57:370-376.
28. Berenson J, Webb I, Hennick K, et al. A phase II dose-ranging trial of single-agent pamidronate for relapsed/refractory multiple myeloma. Blood 1998;92: suppl 4.
29. Moulopoulos LA, Dimoupoulos MA, Alexanian R, et al. Multiple myeloma: MR patterns of response to treatment. Radiology 1994;193:441-446.
30. Schreiman JS, Mcleod R, Kyle RA, et al. Multiple myeloma: evaluation by CT. Radiology 1995;154:483-486.
31. Terpos E. Biochemical markers of bone metabolism im multiple myeloma. Cancer Treatment Reviews 2006;32 (suppl 1):15-19.
32. Rowell NP, Tobias JS. The role of radiotherapy in the management of multiple myeloma. Blood Rev 1991;5:84-89.
33. Adamietz IA, Schober C, Schulte RWM, et al. Radiother Oncol 1991;20:111-116.
34. Rowell NP, Tobias JS. The role of radiotherapy in the management of multiple myeloma. Blood Rev 1991;5:84-89.
35. Jensen ME, Kallmes DE. Percutaneous vertebroplasty in the treatment of malignant spine disease. Cancer J 2002;8:194-206.
36. Cotton A, Dewatre F, Cortet B, Assaker R, Leblond D, Dusquesnoy B, et al. Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up. Radiology 1996;200:525-530.
37. Moreland DB, Landi MK, Grand W. Vertebroplasty: techniques to avoid complications. Spine J 2001;1:66-71.
38. Dudeney S, Lieberman IH, Reinhardt MK, Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. Cancer J 2001;20:2.382-2.387.
39. Phillips FM, McNally TA, Liberman IH, Truumees E. Does kyphoplasty reduce potential for extra-vertebral and intravascular polymethylmethacrylate leakage when compared with vertebroplasty? Proceedings of the NASS 16th Annual Meeting. Spine J 2002;2:19S.
40. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132(4):410-51.
41. Tillman RM. The role of the orthopaedic surgeon in metastatic disease of the appendicular skeleton. Worling Party on Metastatic Bone Disease in Breast Cancer in the UK. J Bone Joint Surg Br 1999;81:1-2.
42. Harrington KD. Orthopaedic management of extremity and pelvic lesions. Clin Orthop 1995;312:136-147.
43. Gamron TA, Sim FH. Surgical treatment for metastatic disease of the pelvis and the proximal end of the femur. Instr Course Lect 2000;49:461-470.
44. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-750.
45. Lahtinen R, Laakso M, Palva I, Virkkunen P, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992;340:1.049-1.052.
46. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:529-530.
47. McCloskey EV, MacLennan IC, Drayson MT, et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 1998;100:317-325.
48. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-bind, comparative trial. Cancer J 2001;7:377-387.
49. Croucher PI, de Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decrease osteolysis, tumor burden and angiogenesis, and increase survival. J Bone Mineral Res 2003;18:482-492.
50. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:1-19.
51. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;62(9):1.115-1.117.
52. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104(1):83-93.
53. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136(12):1.658-1.668.
54. Ruggiero SL. Practical guidelines for the prention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006;2:7-14.
55. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98:3.534-3.540.
56. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Med 2000;5:521-528.
57. Capparelli C, Kostenuik PJ, Morony S, et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000;60:783-787.
58. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1.059-1.066.
59. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002;2(2):106-115.
60. Barillé-Nion S, Bataille R. New insights in the biology and treatment of myeloma-induced bone disease. American Society of Hematology Education Program Book 2003:255-260.